US6054561A
(en)
*
|
1984-02-08 |
2000-04-25 |
Chiron Corporation |
Antigen-binding sites of antibody molecules specific for cancer antigens
|
US5032521A
(en)
*
|
1984-12-05 |
1991-07-16 |
The Salk Institute For Biological Studies |
Monoclonal antibody specific for a mammary tumor cell surface antigen
|
AU601379B2
(en)
*
|
1985-11-07 |
1990-09-13 |
Trustees Of Columbia University In The City Of New York, The |
Antigen indicative of human breast cancer and assays based thereon
|
US5401638A
(en)
*
|
1986-06-04 |
1995-03-28 |
Oncogene Science, Inc. |
Detection and quantification of neu related proteins in the biological fluids of humans
|
US6861511B1
(en)
|
1986-06-04 |
2005-03-01 |
Bayer Corporation |
Detection and quantification of neu related proteins in the biological fluids of humans
|
US4894227A
(en)
*
|
1986-08-01 |
1990-01-16 |
Cetus Corporation |
Composition of immunotoxins with interleukin-2
|
US6004761A
(en)
*
|
1986-11-19 |
1999-12-21 |
Sanofi |
Method for detecting cancer using monoclonal antibodies to new mucin epitopes
|
NZ222509A
(en)
*
|
1986-11-19 |
1993-03-26 |
Oncogen |
Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
|
US4863726A
(en)
*
|
1987-05-29 |
1989-09-05 |
Cetus Corporation |
Combination therapy using immunotoxins with interleukin-2
|
US5084266A
(en)
*
|
1988-02-03 |
1992-01-28 |
The University Of Melbourne |
Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
|
US5681543A
(en)
*
|
1988-02-29 |
1997-10-28 |
Shering Aktiengesellschaft |
Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
|
US5811267A
(en)
*
|
1990-10-29 |
1998-09-22 |
Chiron Corporation |
Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
|
US5948647A
(en)
*
|
1990-10-29 |
1999-09-07 |
Chiron Corporation |
Nucleic acids encoding antigen-binding sites specific for cancer antigens
|
US5849877A
(en)
*
|
1990-10-29 |
1998-12-15 |
Chiron Corporation |
Antigen-binding sites of antibody molecules specific for cancer antigens
|
US5292524A
(en)
*
|
1991-09-06 |
1994-03-08 |
California Institute Of Technology |
Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
|
EP1514934B1
(de)
*
|
1992-02-06 |
2008-12-31 |
Novartis Vaccines and Diagnostics, Inc. |
Marker für Krebs und biosynthetisches Bindeprotein dafür
|
US7255851B2
(en)
*
|
1994-07-01 |
2007-08-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-invasive localization of a light-emitting conjugate in a mammal
|
US20030086922A1
(en)
*
|
1994-12-02 |
2003-05-08 |
David B. Ring |
Method of promoting an immune response with a bispecific antibody
|
US6416960B1
(en)
|
1996-08-08 |
2002-07-09 |
Prolume, Ltd. |
Detection and visualization of neoplastic tissues and other tissues
|
GB9906380D0
(en)
*
|
1999-03-19 |
1999-05-12 |
Melvin William T |
Monoclonal antibodies specific for cypibi
|
FR2811323B1
(fr)
*
|
2000-07-07 |
2006-10-06 |
Fuma Tech Gmbh |
Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
|
DE10141937A1
(de)
*
|
2001-08-28 |
2003-03-27 |
Alfred Schmidt |
Markierung der Aromatase
|
EP1438583B1
(de)
|
2001-09-20 |
2009-09-16 |
Board of Regents, The University of Texas System |
Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests
|
US20040166490A1
(en)
*
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20040126762A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Morris David W. |
Novel compositions and methods in cancer
|
US20040180344A1
(en)
*
|
2003-03-14 |
2004-09-16 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20040197778A1
(en)
*
|
2002-12-26 |
2004-10-07 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US20060040262A1
(en)
*
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
AU2003218350A1
(en)
*
|
2002-03-21 |
2003-10-08 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
CA2501188C
(en)
|
2002-07-15 |
2012-05-15 |
Board Of Regents, The University Of Texas System |
Combinatorial protein library screening by periplasmic expression
|
US7794716B2
(en)
|
2002-07-25 |
2010-09-14 |
Glenveigh Pharmaceuticals, Llc |
Antibody composition and passive immunization against pregnancy-induced hypertension
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
US7767387B2
(en)
*
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
JP2007524362A
(ja)
|
2003-02-14 |
2007-08-30 |
サイグレス ディスカバリー, インコーポレイテッド |
癌における治療gpcr標的
|
US20070218071A1
(en)
*
|
2003-09-15 |
2007-09-20 |
Morris David W |
Novel therapeutic targets in cancer
|
US20070281896A1
(en)
*
|
2003-09-30 |
2007-12-06 |
Morris David W |
Novel compositions and methods in cancer
|
CA2554729A1
(en)
*
|
2004-01-27 |
2005-08-11 |
University Of Southern California |
Polymer-bound antibody cancer therapeutic agent
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
ATE487484T1
(de)
|
2004-09-18 |
2010-11-15 |
Univ Maryland |
Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
|
AU2005290238A1
(en)
|
2004-09-18 |
2006-04-06 |
Department Of Veterans Affairs |
Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof
|
EP3796003A1
(de)
|
2005-04-04 |
2021-03-24 |
Biogen MA Inc. |
Verfahren zur bewertung einer immunreaktion auf ein therapeutisches mittel
|
AU2006235258A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cancer-related genes
|
US20090214536A1
(en)
|
2005-04-07 |
2009-08-27 |
Guoying Yu |
CACNA1E in Cancer Diagnosis, Detection and Treatment
|
US8124351B2
(en)
|
2005-11-18 |
2012-02-28 |
Board Of Regents, The University Of Texas System |
Quantification of fusion proteins and their activity from chromosomal translocation
|
AU2007269714A1
(en)
|
2006-07-03 |
2008-01-10 |
Charles David Adair |
Composition for modulating the expression of cell adhesion molecules
|
CA2671264C
(en)
|
2006-11-30 |
2015-11-24 |
Research Development Foundation |
Improved immunoglobulin libraries
|
CA2674949A1
(en)
|
2007-01-12 |
2008-07-24 |
J. Marc Simard |
Targeting ncca-atp channel for organ protection following ischemic episode
|
KR100855299B1
(ko)
*
|
2007-02-16 |
2008-08-29 |
건국대학교 산학협력단 |
인간 il-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 il-32측정법
|
CA2685675C
(en)
|
2007-05-01 |
2016-02-16 |
Research Development Foundation |
Immunoglobulin fc libraries
|
CA2691539C
(en)
|
2007-06-21 |
2014-08-26 |
Angelica Therapeutics, Inc. |
Modified toxins
|
EP3293269A1
(de)
|
2007-08-03 |
2018-03-14 |
MUSC Foundation For Research Development |
Menschliche monoklonale antikörper und verfahren zu ihrer herstellung
|
WO2009102509A2
(en)
|
2008-01-10 |
2009-08-20 |
Research Development Foundation |
Vaccines and diagnostics for the ehrlichioses
|
US8470314B2
(en)
*
|
2008-02-29 |
2013-06-25 |
Angelica Therapeutics, Inc. |
Modified toxins
|
US20100082438A1
(en)
*
|
2008-10-01 |
2010-04-01 |
Ronnie Jack Garmon |
Methods and systems for customer performance scoring
|
CN102272157B
(zh)
|
2008-11-07 |
2015-11-25 |
研究发展基金会 |
用于抑制cripto/grp78复合物形成和信号的组合物和方法
|
US20110287088A1
(en)
|
2008-12-03 |
2011-11-24 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
WO2011044553A1
(en)
|
2009-10-11 |
2011-04-14 |
Biogen Idec Ma Inc. |
Anti-vla-4 related assays
|
WO2011062997A2
(en)
|
2009-11-17 |
2011-05-26 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
WO2012065161A2
(en)
|
2010-11-12 |
2012-05-18 |
Scott & White Healthcare |
Antibodies to tumor endothelial marker 8
|
EP2673299B1
(de)
|
2011-02-07 |
2017-05-10 |
Research Development Foundation |
Manipulierte immunglobulin-fc-polypeptide
|
CN103747802B
(zh)
|
2011-04-01 |
2018-06-01 |
伊缪诺金公司 |
用于增加folr1癌症治疗的功效的方法
|
DK2739310T3
(en)
|
2011-08-05 |
2018-07-16 |
Res Found Dev |
Improved methods and compositions for modulating OLFML3-mediated angiogenesis
|
WO2013025834A2
(en)
|
2011-08-15 |
2013-02-21 |
The University Of Chicago |
Compositions and methods related to antibodies to staphylococcal protein a
|
HUE044838T2
(hu)
|
2012-03-20 |
2019-11-28 |
Biogen Ma Inc |
JCV neutralizáló antitestek
|
EP2841101B1
(de)
|
2012-04-26 |
2019-08-07 |
University Of Chicago |
Zusammensetzungen und verfahren in zusammenhang mit antikörpern zur neutralisierung der koagulaseaktivität bei einer staphylococcus-aureus-erkrankung
|
US9683030B2
(en)
|
2012-05-10 |
2017-06-20 |
Massachusetts Institute Of Technology |
Agents for influenza neutralization
|
WO2014025546A2
(en)
|
2012-08-07 |
2014-02-13 |
Massachusetts Institute Of Technology |
Anti-dengue virus antibodies and uses thereof
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
DK2912064T3
(da)
|
2012-10-24 |
2019-07-22 |
Res Found Dev |
Jam-c-antistoffer og fremgangsmåder til behandling af cancer
|
WO2014127211A1
(en)
|
2013-02-15 |
2014-08-21 |
Research Development Foundation |
Deimmunized gelonin molecules and therapies
|
DK2968503T3
(en)
|
2013-03-15 |
2018-12-03 |
Intrinsic Lifesciences Llc |
ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
|
CA2902905A1
(en)
|
2013-03-15 |
2014-09-25 |
Claude Geoffrey Davis |
Modified toxins
|
WO2014144666A2
(en)
|
2013-03-15 |
2014-09-18 |
The University Of Chicago |
Methods and compositions related to t-cell activity
|
PE20152005A1
(es)
|
2013-03-15 |
2016-01-29 |
Bayer Healthcare Llc |
Dominios gla como agentes terapeuticos
|
US10526375B2
(en)
|
2013-06-05 |
2020-01-07 |
Massachusetts Institute Of Technology |
Human Adaptation of H7 HA
|
CA2916694C
(en)
|
2013-06-28 |
2023-01-17 |
Baylor Research Institute |
Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
|
CA2921652A1
(en)
|
2013-08-21 |
2015-02-26 |
Manuel A. Riquelme |
Compositions and methods for targeting connexin hemichannels
|
AU2014312086B2
(en)
|
2013-08-30 |
2020-03-12 |
Immunogen, Inc. |
Antibodies and assays for detection of folate receptor 1
|
US20170002064A1
(en)
|
2013-11-08 |
2017-01-05 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
CA2936833A1
(en)
|
2014-01-13 |
2015-07-16 |
Baylor Research Institute |
Novel vaccines against hpv and hpv-related diseases
|
US10059775B2
(en)
|
2014-01-29 |
2018-08-28 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
|
CN106413749B
(zh)
|
2014-02-11 |
2022-04-05 |
麻省理工学院 |
新颖全谱抗登革抗体
|
RU2744836C2
(ru)
|
2014-05-08 |
2021-03-16 |
Новодиакс, Инк. |
Прямой иммуногистохимический анализ
|
WO2015179435A1
(en)
|
2014-05-19 |
2015-11-26 |
Bayer Healthcare Llc |
Optimized humanized monoclonal antibodies against activated protein c and uses thereof
|
EA038798B1
(ru)
|
2014-08-27 |
2021-10-21 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Анти-b7h3 антитела и связанные соединения и применение
|
EP3197915A4
(de)
|
2014-09-22 |
2018-12-19 |
Intrinsic Lifesciences LLC |
Humanisierte anti-hepcidin-antikörper und verwendungen davon
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
AU2015346444A1
(en)
|
2014-11-12 |
2017-05-04 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
CA2976074A1
(en)
|
2015-02-09 |
2016-08-18 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
|
CA2976236A1
(en)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
CA2977499C
(en)
|
2015-02-25 |
2023-10-03 |
Vanderbilt University |
Antibody-mediated neutralization of marburg virus
|
WO2017040380A2
(en)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Engineered antibody fc variants
|
EP3373968A4
(de)
|
2015-11-09 |
2019-06-26 |
The Children's Hospital of Philadelphia |
Glypican 2 als tumormarker und therapeutikum
|
KR20180100122A
(ko)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
MX2018006613A
(es)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
|
CN108601811A
(zh)
|
2015-12-04 |
2018-09-28 |
得克萨斯州大学系统董事会 |
用于免疫治疗的slc45a2肽
|
CA3015839A1
(en)
|
2016-02-26 |
2017-08-31 |
The Board Of Regents Of The University Of Texas System |
Connexin (cx)43 hemichannel-binding antibodies and uses thereof
|
JP7241541B2
(ja)
|
2016-03-29 |
2023-03-17 |
エスティーキューブ,インコーポレイテッド |
グリコシル化pd-l1に特異的な二重機能抗体およびその使用方法
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
EP3478162A4
(de)
|
2016-07-01 |
2020-07-29 |
The General Hospital Corporation |
Granzym-b-gerichtete bildgebung und therapie
|
WO2018017673A1
(en)
|
2016-07-20 |
2018-01-25 |
Stcube, Inc. |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
|
WO2018126183A2
(en)
|
2016-12-29 |
2018-07-05 |
The General Hospital Corporation |
Her3 peptides for imaging and radiotherapy
|
KR20200024158A
(ko)
|
2017-05-31 |
2020-03-06 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
EP3630835A1
(de)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Antikörper und moleküle, die immunspezifisch an btn1a1 binden, und therapeutische verwendungen davon
|
KR20200026209A
(ko)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
SG11202000387YA
(en)
|
2017-08-25 |
2020-03-30 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
EP3679127A1
(de)
|
2017-09-05 |
2020-07-15 |
GLAdiator Biosciences, Inc. |
Abgabe von nutzlasten an stammzellen
|
US11464784B2
(en)
|
2017-09-15 |
2022-10-11 |
The Regents Of The University Of California |
Inhibition of aminocylase 3 (AA3) in the treatment of cancer
|
EP4116327A1
(de)
|
2017-10-11 |
2023-01-11 |
Board Of Regents, The University Of Texas System |
Menschliche pd-l1-antikörper und verfahren zu ihrer verwendung
|
US11851478B2
(en)
|
2018-01-05 |
2023-12-26 |
Vanderbilt University |
Antibody-mediated neutralization of chikungunya virus
|
WO2019169212A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
WO2019182896A1
(en)
|
2018-03-23 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
EP3849608B1
(de)
|
2018-09-13 |
2023-08-30 |
The Board of Regents of The University of Texas System |
Neue lilrb4-antikörper und verwendungen davon
|
EP4219550A1
(de)
|
2018-11-02 |
2023-08-02 |
Oklahoma Medical Research Foundation |
Monoklonale antikörper gegen etld1 und verwendungen davon
|
CN113423465A
(zh)
|
2018-11-28 |
2021-09-21 |
俄勒冈健康与科学大学 |
治疗性的因子xii抗体
|
EP3924354A1
(de)
|
2019-02-13 |
2021-12-22 |
Cytosite Biopharma Inc. |
Granzym-b-gerichtete bildgebung und therapie
|
CN114555807A
(zh)
|
2019-07-19 |
2022-05-27 |
费城儿童医院 |
包含磷脂酰肌醇蛋白聚糖2结合结构域的嵌合抗原受体
|
JP2022541652A
(ja)
|
2019-07-26 |
2022-09-26 |
ヴァンダービルト ユニバーシティ |
エンテロウイルスd68に対するヒトモノクローナル抗体
|
US20220411511A1
(en)
|
2019-09-26 |
2022-12-29 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
US20220356248A1
(en)
|
2019-10-09 |
2022-11-10 |
Stcube & Co |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
WO2021163265A1
(en)
|
2020-02-11 |
2021-08-19 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
UY39135A
(es)
|
2020-03-26 |
2021-10-29 |
Univ Vanderbilt |
ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
GB202105804D0
(en)
|
2020-11-20 |
2021-06-09 |
Univ Cape Town |
Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
EP4304660A1
(de)
|
2021-03-08 |
2024-01-17 |
ImmunoGen, Inc. |
Verfahren zur erhöhung der wirksamkeit von auf adam9 abzielenden immunkonjugaten zur behandlung von krebs
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
WO2023192976A1
(en)
|
2022-04-01 |
2023-10-05 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
WO2024040020A1
(en)
|
2022-08-15 |
2024-02-22 |
Absci Corporation |
Quantitative affinity activity specific cell enrichment
|